These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 8551526)

  • 1. Comparison of serum CA15-3 and CEA in breast cancer.
    Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
    Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
    Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
    Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
    Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
    Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
    J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
    Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
    World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
    Chen C; Chen Q; Dong Y; Liu X
    Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.
    Yamamoto N; Nakayama T; Kajita M; Miyake T; Iwamoto T; Kim SJ; Sakai A; Ishihara H; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Feb; 132(1):165-73. PubMed ID: 21594664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evaluation of combined scintimammography and tumor markers in breast cancer patients.
    Mangkharak J; Patanachak C; Podhisuwan K; Pleehachinda R
    Anticancer Res; 1997; 17(3B):1611-4. PubMed ID: 9179203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
    Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
    Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
    Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
    Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
    El-Attar NI; Gaefar HA
    Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnostic value of combined detection of TPS, CA153 and CEA in breast cancer].
    Zheng H; Luo RC
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1293-4, 1298. PubMed ID: 16234113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
    Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
    Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
    Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
    Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
    Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
    J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.